BioCentury
ARTICLE | Company News

Myriad Genetics, Tesaro deal

July 1, 2013 7:00 AM UTC

Tesaro will use Myriad's BRACAnalysis test to select patients likely to respond to the Tesaro's niraparib for enrollment in two Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor. Myriad markets BRACAnalysis to assess a woman's risk of developing breast or ovarian cancer based on detecting genetic mutations in the breast cancer 1 early onset (BRCA1) and BRACA2 genes.

Mid-2013, Tesaro plans to start a double-blind, placebo-controlled, international Phase III trial to evaluate niraparib in about 360 patients with platinum-sensitive, relapsed ovarian cancer. A second international Phase III trial is expected to start this half and will enroll about 300 patients previously treated with an anthracycline and a taxane with advanced or metastatic breast cancer carrying BRCA1 or BRCA2 mutations. ...